ArticleNeurosurgery2026
Safety of Prefrontal Cortex Biopsies During Deep Brain Stimulation Procedures.
Article in Neurosurgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A transcriptional program associated with neurotransmission in the living human brain.Molecular psychiatry · 2026Article
- A study of gene expression in the living human brain.Molecular psychiatry · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
BACKGROUND AND
objectivesA goal of medical research is to advance knowledge of the molecular biology underlying human brain function. Yet, few studies of human brain biology have been performed using brain tissue from living people. This is due to the lack of safe approaches to sampling the living human brain for rigorous scientific inquiry. The Living Brain Project (LBP) developed a method to biopsy a small volume of prefrontal cortex (PFC) tissue during deep brain stimulation (DBS) lead placement procedures. The objective of this LBP report was to establish the safety of the PFC biopsy approach.
methodsAcute adverse events (ie, infection, intracranial hemorrhage [ICH], and seizures) were tracked after 1152 DBS procedures performed on 590 patients. A PFC biopsy was obtained in 652 procedures ("biopsy group"), and no biopsy was obtained in 500 procedures ("nonbiopsy group"). Cognitive health was assessed at baseline and 1 year after DBS surgery for 144 patients. Rates of acute adverse events and changes in cognitive health were compared between the biopsy and nonbiopsy groups.
resultsNo infections occurred in either group. No statistically significant difference in ICH rate was observed between groups (1.7% biopsy group vs 1.4% nonbiopsy group; χ 2 test P -value = .88), and this observation held regardless of the anatomical location or the clinical severity of the ICH. No statistically significant difference in seizure rate was observed between groups (0.2% biopsy group vs 0.4% nonbiopsy group; P -value = .82). No statistically significant associations were observed between number of biopsies and changes in cognitive health over time.
conclusionDBS procedures involving PFC biopsies for the LBP demonstrate a safety profile comparable with DBS procedures without biopsies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.